CStone Pharmaceuticals to Present Promising CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) Clinical Data at ASCO 2026 for NSCLC and Solid Tumors
CStone Pharmaceuticals ASCO 2026 Preview: Major Clinical Upd...
Sign in to continue:
CStone Pharmaceuticals ASCO 2026 Preview: Major Clinical Upd...
Binhai Investment 2026 Q1 Operating Highlights: In-Depth Inv...
Key Highlights Six abstracts from clinical studies of t...
China Isotope & Radiation Corporation 2025 Annual Report: Ke...
Detailed Insights: LM-364 ("Nectin-4 TME ADC") Innovati...
Jiangsu Lopal Tech. Group Co., Ltd. Announces Acquisition of...
Wise Living Technology Co., Ltd - Annual Report 2025: Key In...
Jiangsu Lopal Tech. Group Co., Ltd. Announces Strategic Inve...
DIT Group Limited 2025 ESG Report – Key Insights for Investo...
MemeStrategy, Inc. Announces World's First Tokenized Pokémon...